Maze Therapeutics has dosed the first subject in the Phase II HORIZON study to evaluate its oral apolipoprotein L1 (APOL1) inhibitor, MZE829, in treating subjects with APOL1 kidney disease (AKD).
The Angami Krotho Delhi (AKD) celebrated its 37th Sekrenyi Festival on February 28 at Nagaland House, New Delhi.
President Anura Kumara Dissanayake’s (AKD) recent visit to Jaffna received significant social media attention due to posting of a less than a minute-long video of him going for a walk there. An ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results